SCM
ALLO icon

Superstring Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Superstring Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-478,115
Closed -$1.34M – 40
2024
Q3 		$1.34M Sell
478,115
-211,797
-31% -$565K 1.17% 17
2024
Q2 		$1.61M Buy
689,912
+168,663
+32% +$498K 2.03% 14
2024
Q1 		$2.33M Buy
521,249
+299,137
+135% +$1.25M 1.54% 20
2023
Q4 		$713K Buy
+222,112
New +$630K 0.51% 26

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Superstring Capital Management's ALLO Position: Q4 2024 in Review

Superstring Capital Management sold out of Allogene Therapeutics (ALLO) in Q4 2024, closing a stake of 478,115 shares — an estimated $1.34M sold.

Superstring Capital Management first reported a position in ALLO in Q4 2023 and held it in 4 quarters. The position peaked at $2.33M in Q1 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

  • Superstring Capital Management reported no remaining Allogene Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Superstring Capital Management sold 478,115 Allogene Therapeutics shares in Q4 2024, an estimated $1.34M.
  • Superstring Capital Management first reported a position in Allogene Therapeutics in Q4 2023 and held it in 4 quarters.
  • Superstring Capital Management's Allogene Therapeutics position peaked at $2.33M in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on Superstring Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.